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The 6-minute walk test (6MWT) is a simple, 
feasible test reflective of daily life activity in 
patients with chronic heart failure (HF) and has 
been used as a measure of functional status [1]. 
The 6MWT is also valuable to assess response to 
therapeutic intervention in patients with moderate 
to severe HF [2]. Prior studies demonstrated that 
the change in the 6-minute walk distance (6MWD) 
from admission-to-discharge was an independent 
predictor of survival [3] and worsening HF requir-
ing rehospitalizaiton [4]. The prognostic effect of 
6MWT in HF was the basis for its use as a primary 
endpoint in clinical trials. The aim of this study is 
to identify determinants of improvement in 6MWD 
from admission to discharge, and to determine 
whether the degree of decongesting patients with 
acute systolic HF with diuretics was a predictor of 
improvement in walking distance.
The ESCAPE trial randomized 433 patients 
with acute HF with ejection fraction (EF) ≤ 30% 
to either clinical assessment alone versus clinical 
assessment guided by pulmonary artery catheteri-
zation (PAC). The study showed that the PAC did 
not improve or worsen HF outcomes [5, 6]. 6MWD 
was measured in feet, and assessed at multiple 
time points including admission and discharge. 
The degree of decongestion was examined through 
clinical, laboratory, echocardiographic and PAC 
variables (Table 1). Continuous variables were 
expressed as median and interquartile range, and 
were reported as counts and percentages and 
compared using Mann-Whitney test and categori-
cal variables were compared using c2. Longitudi-
nal comparison of the 6MWD on admission and 
discharge was performed using paired sample 
T-test. The association between the improvement 
in 6MWD and a selection of variables was exam-
ined using Spearman’s correlation. A multivari-
able regression model was performed to identify 
independent predictors of improvement in 6MWD. 
Two hundred twenty two patients (mean age 
55 years, 78% men) had recorded measurements 
for 6MWD on admission and discharge. After 
7.9 ± 5.6 days, the distance walked increased from 
601 ± 375 feet to 806 ± 390 feet (p < 0.001). The 
average improvement in 6MWD from admission-
to-discharge was 205 feet (median: 160 feet; 49 m). 
110 patients had an improvement in 6MWD 
> 160 feet and 112 experienced an improvement 
in 6MWD ≤ 160 feet. Compared with patients with 
improvement in 6MWD ≤ 160 feet, those with 
improvement in 6MWD > 160 feet were younger 
(p = 0.009), with a lower 6MWD on admission 
(p < 0.001), lower frequency of atrial fibrillation 
(p = 0.036), lower frequency of aortic stenosis 
(p = 0.007) and a trend towards lower frequency 
of angina pectoris (p = 0.088). No difference was 
found between the groups with regard to the degree 
of decongestion or improvement in cardiac output 
from admission-to-discharge (Table 1). There were 
also no significant differences between the groups 
in baseline left and right ventricular EF. 
Correlation analysis in the whole cohort (222 
cases) showed that the improvement in 6MWD was 
inversely correlated with patients’ age (n = 222, 
r = –0.179, p = 0.008) and baseline 6MWD 
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Table 1. Comparison of clinical, echocardiographic and hemodynamic characteristics of ESCAPE trial 
patients according to whether improvement in 6-minute walk distance (6MWD) from admission-to-
-discharge was > or ≤ 160 feet (49 m).
6MWD improvement  
> 160 feet (n = 110)
6MWD improvement  
£ 160 feet (n = 112)
P
Baseline demographics
Age [years], median (IQR] 53.5 (42, 61.5) 58 (48, 68) 0.009
Male sex 79.1% (87/110) 76.8% (86/112) 0.679
White race 50.9% (56/110) 65.2% (73/112) 0.031
Black race 29.1% (32/110) 19.6% (22/112) 0.101
Baseline 6MWD [feet], median (IQR) 487 (245, 681) 706 (369, 993) < 0.001
Baseline 6MWD [m], median (IQR) 148 (75, 208) 215 (112, 303) < 0.001
Comorbidities
Ischemic etiology of HF 41.8% (46/110) 52.3% (58/111) 0.120
Atrial fibrillation 20% (22/110) 32.4% (36/111) 0.036
Angina pectoris 25.5% (28/110) 36% (40/111) 0.088
Coronary artery bypass graft 26.4% (29/110) 30.6% (34/111) 0.482
Chronic obstructive pulmonary disease 15.5% (17/110) 16.2% (18/111) 0.877
Mitral regurge 9.1% (10/110) 12.6% (14/111) 0.400
Aortic stenosis 0% (0/110) 6.3% (7/111) 0.007
Stroke 8.2% (9/110) 8.1% (9/111) 0.984
Malignancy 3.6% (4/110) 7.2% (8/111) 0.241
Depression 19.1% (21/110) 13.5% (15/111) 0.262
Clinical variables of decongestion
Reduction in 6MWD [feet], median (IQR) 356 (254, 574) 35 (–80, 105) –
Weight loss [kg], median (IQR) 2.5 (0.91, 4.99) 2.5 (0.9, 5.54) 0.633
Resolution of JVD on discharge 62% (62/100) 64.7% (66/102) 0.204
Resolution of orthopnea on discharge 57.1% (60/105) 49.5% (49/99) 0.274
Resolution of HJR on discharge 70.1% (61/87) 57.6% (57/99) 0.076
Laboratory variables of decongestion
BNP reduction [pg/mL], median (IQR) 63 (–51, 327) 163 (27, 520) 0.058
PAC variables of decongestion
RAP change [mm Hg], median (IQR) –3 (–8, 0) –2 (–5.5, 2) 0.408
PCWP change [mm Hg], median (IQR) –7 (–15, –3) –6 (–13, –1) 0.347
PASP change [mm Hg], median (IQR) –11.5 (–21.5, 0) –9 (–18.8, –2.25) 0.792
PADP change [mm Hg], median (IQR) –7 (–13, –1.75) –5.5 (–13, 0) 0.665
CI change [L/min/m2], median (IQR) 0.4 (–0.08, 0.7) 0.38 (–0.09, 0.79) 0.962
CO change [L/min], median (IQR) 0.7(–0.2, 1.4) 0.8 (–0.19, 1.28) 0.964
Echocardiographic variables of decongestion
IVC inspiration change [cm], median (IQR) –0.41 (–0.79, 0.12) –0.21 (–0.77, 0.19) 0.366
IVC expiration change [cm], median (IQR) –0.4 (–0.88, 0.09) –0.18 (–0.45, 0.21) 0.126
IVC collapsibility index change [cm], median (IQR) 3.91 (–3.98, 19.86) 1.85 (–8.87, 16.54) 0.574
Left ventricular EF [%], median (IQR)* 19.4 (11, 26.7) 17.6 (12.6, 23.3) 0.777
Right ventricular EF [%], median (IQR)* 22 (12.7, 30.8) 24.3 (18.1, 29.1) 0.823
These echocardiographic variables were recorded at baseline; HF — heart failure; JVD — jugular venous distension; HJR — hepatojugular 
reflux, BNP — B-type natriuretic peptide; PAC — pulmonary artery catherization; RAP — right atrial pressure; PCWP — pulmonary capillary 
wedge pressure; PASP — pulmonary artery systolic pressure; PADP — pulmonary artery diastolic pressure; CI — cardiac index; CO — cardiac 
output; IVC — inferior vena cava; EF — ejection fraction; IQR — interquartile range
(n = 222, r = –0.358, p < 0.001). Nonetheless, 
no association was found between admission-
to-discharge improvement in 6MWD and ad-
mission-to-discharge weight loss (p = 0.701), 
admission-to-discharge reduction in right atrial 
pressure (p = 0.502), admission-to-discharge 
reduction in pulmonary capillary wedge pressure 
(p = 0.370), admission-to-discharge reduction 
in inferior vena cava diameter during inspiration 
(p = 0.807) and expiration (p = 0.386), and admis-
sion-to-discharge reduction in B-type natriuretic 
peptide (BNP; p = 0.081) (Fig. 1). Multivariable lin-
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ear regression analysis revealed that patients age 
(standardized b = –0.239, p = 0.022) and 6MWD 
on admission (standardized b = –0.529, p < 0.001) 
were independent predictors of improvement 
in 6MWD after adjusting for EF (standardized 
b = 0.016, p = 0.869), body mass index (stand-
ardized b = 0.146, p = 0.150) and reduction in 
BNP from admission-to-discharge (standardized 
b = 0.061, p = 0.529). 
It was shown in this analysis that younger age 
and lower 6MWD on admission determined the 
improvement in walking distance from admission-
-to-discharge in patients with acute HF and EF 
≤ 30%. These results remained unaltered on mul-
tivariate analysis. These finding are in-line with 
prior work by Passantino et al. [3] who found that 
age and 6MWD at baseline were inversely related 
to the increase in distance walked. We found no as-
sociation between the degree of decongestion and the 
improvement in walking distance from admission to 
discharge. The degree of decongestion was thoroughly 
evaluated in our study through various clinical, labo-
ratory, echocardiographic, and central hemodynamic 
variables of decongestion via the PAC. The present 
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Figure 1. A–I. Scatter plots illustrating the association between various variables and improvement in 6-minute walk 
distance (6MWD) from admission to discharge in patients with acute heart failure enrolled in the ESCAPE trial; BNP — 
B-type natriretic peptide; CO — cardiac output; IVC — inferior vena cava; PCWP — pulmonary capillary wedge pressure; 
RAP — right atrial pressure.
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findings suggest that diuresis is not the main deter-
minant for the improvement in the functional status of 
HF patients. Prior studies show that the 6MWD was 
sensitive to short-term changes in drug therapy [7]; 
for example, angiotensin converting enzyme inhibitors 
and beta-blockers were found to significantly improve 
submaximal exercise tolerance, as assessed by the 
6MWD [8–10]. Unfortunately the lack of sufficient data 
on medication in the limited access dataset, prevented 
the assessment of the effect of various medications on 
the improvement in 6MWD. 
There are several hypotheses to explain the 
lack of association between decongestion and 
improvement in walking distance. For example, 
a patient with predominantly left-sided failure will 
initially have symptoms of pulmonary conges-
tion, but after small volume diuresis, symptoms 
will improve: in this scenario, one would expect 
a significant improvement in 6MWD despite only 
modest diuresis. Another scenario is a patient 
with hypertensive pulmonary edema who may 
experience relief of dyspnea with intravenous 
nitroglycerin causing venodilation without change 
in his volume status. Also, the functional capacity 
of HF patients is related not only to central “i.e. 
cardiac” factors, but also to “peripheral factor” 
like endothelial dysfunction, muscle performance, 
ventilatory inefficiency, which is less sensitive to 
improvements in the hemodynamic profile. Fur-
thermore, the intensive diuretic therapy could lead 
to electrolytes abnormalities causing paradoxical 
worsening of fatigue and functional capacity. More 
importantly, the observation that patients with 
> 160 feet (49 m) improvement in walking distance 
had lower admission 6MWD best exemplifies that 
the phenomenon of “regression to the mean” — 
which describes the tendency of an extreme meas-
urement on a first occasion to become less extreme 
when checked again — may have been responsible 
for masking the effect of decongestion on improve-
ment in 6MWD. In this study, it was easier for 
a patient to have a larger improvement in 6MWD 
if the initial walking distance was too low. This 
statistical phenomenon happens in studies when 
repeated measurements are made for the same 
patient. Regression to the mean is concerning if 
the examined variable exhibits significant within-
subject variability on repeated measurements and 
this typically occurs if there is a high threshold for 
trial enrollment, making the entry measurements 
away from the patients’ true mean. This represents 
a limitation to our study and therefore our results 
have to be interpreted with caution. Futher studies 
are needed to confirm our findings.
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